Keele Research Repository

Article

Kessler, D, Burns, A, Tallon, D, Lewis, G, MacNeill, S, Round, J, Hollingworth, W, Chew-Graham, CA, Anderson, I, Campbell, J, Dickens, C, Macleod, U, Gilbody, S, Davies, S, Peters, TJ and Wiles, N (2018) Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technology Assessment, 22 (63). 1 - 136.

Kessler, DS, MacNeil, SJ, Tallon, D, Lewis, G, Peters, TJ, Hollingworth, W, Round, J, Burns, A, Chew-Graham, CA, Anderson, IM, SHEPHERD, T, Campbell, J, Dickens, CM, Carter, M, Jenkinson, C, Macleod, U, Gibson, H, Davies, S and Wiles, NJ (2018) MIRtazapine added to SSRIs or SNRIs for Treatment Resistant Depression in Primary Care: a placebo controlled randomised trial (MIR). BMJ, 363.

Kessler, DS, MacNeill, SJ, Tallon, D, Lewis, G, Peters, TJ, Hollingworth, W, Round, J, Burns, A, Chew-Graham, CA, Anderson, IM, Shepherd, T, Campbell, J, Dickens, CM, Carter, M, Jenkinson, C, Macleod, U, Gibson, H, Davies, S and Wiles, NJ (2018) Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ, 363. k4218 - ?.